Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

Video content above is prompted by the following:

• What regimens have you found to offer the most favorable toxicity profile? How do you personalize treatment to minimize patient burden?
• What are your preferred strategies for patients who have completed pembrolizumab in the adjuvant setting?
• How does the timing of recurrence relative to adjuvant therapy completion influence your treatment selection?
• Please discuss which patients might still be candidates for initial active surveillance. Which factors prompt you to consider active surveillance rather than immediate systemic therapy?